WaferGen Bio Financial Ratios

WaferGen Bio systems Inc -- USA Stock  

USD 6.9  0.00  0.00%

Please harness WaferGen Bio systems fundamental data analysis to find out if markets are presently mispricing the firm. We found thirty-one available indicators for WaferGen Bio systems which can be compared to its rivals. To make sure the equity is not overpriced, please check out all WaferGen Bio systems fundamentals including its Price to Book, Cash Flow from Operations, Z Score, as well as the relationship between Cash and Equivalents and Total Asset . Given that WaferGen Bio systems has Number of Shares Shorted of 240.41 K, we strongly advise you confirm WaferGen Bio systems prevalent market performance to make sure the company can sustain itself down the road.Use WaferGen Bio to protect against small markets fluctuations. The stock experiences normal downward trend, but the immediate impact on correlations cannot be determined at the moment . Check odds of WaferGen Bio to be traded at $6.83 in 30 days

WaferGen Bio Company Summary

WaferGen Bio competes with Agilent Technologies, Ingersoll Rand, Sensata Technologies, Visualant, and ELECTRO SENSORS. It offers SmartChip RealTime polymerase chain reaction system which offer a suite of gene expression and genome analysis technologies enabling biomarker discovery and validation on a single platform with the sensitivity and accuracy of PCR. WaferGen Biosystems Incs SmartChip RealTime PCR system consists of two instrumentation components comprising a SmartChip MultiSample NanoDispenser for applying sample assay and reaction mix to the SmartChip Panels and a SmartChip Cycler for thermal cycling and collecting data from the realtime PCR assays. It also offer SmartChip SingleCell Isolation System which isolates thousands of single cells and processes specific cells for analysis SmartChip Target Enrichment system that amplifies the targets of interest through PCR and Apollo 324TM library preparation System a walkaway automation platform that offers DNA RNASeq and ChIPSeq library preparation kits for analysis on NGS platforms. WaferGen Biosystems Inc focuses on providing its solutions to researchers who perform genetic analysis and cell biology primarily at pharmaceutical and biotech companies academic and private research centers and diagnostics companies involved in biomarker research. WaferGen Biosystems Inc. was founded in 2002 and is headquartered in Fremont California.

WaferGen Bio Shares Owned by Institutions vs Cash per Share

WaferGen Bio systems Inc is rated first in shares owned by institutions category among related companies. It is rated second in cash per share category among related companies fabricating about  0.23  of Cash per Share per Shares Owned by Institutions. The ratio of Shares Owned by Institutions to Cash per Share for WaferGen Bio systems Inc is roughly  4.26 

WaferGen Bio Market Fundamentals

 Change(%) 0.00%
 Change0.00 Price Moved None
< 91% 

Chance of Financial Distress

WaferGen Bio systems Inc has more than 91 (%) percent chance of experiencing financial distress in the next 2 years of operations. More Info


Compare WaferGen Bio To Peers
Rolland Carlson CEO and President and Director, Ph.D
Ivan Trifunovich Executive Chairman, Ph.D
More Executives

Opportunity Range

December 16, 2017 Opportunity Range